Nyrada Inc (ASX: $NYR) Brain Injury program update

Nyrada Inc (ASX: $NYR) provided an update on its Brain Injury program, announcing the completion of two key safety studies supporting the safety and tolerability of its lead Brain Injury drug candidate NYR-BI03. The studies, conducted under Good Laboratory Practice (GLP) conditions, included AMES and hERG in vitro studies, both of which demonstrated the requisite safety and tolerability of NYR-BI03. Nyrada remains on track to commence its first in-human Phase I clinical trial for NYR-BI03 in late CY2024.

Executive commentary on NYR-BI03 safety studies

Nyrada is pleased to announce the positive outcomes of the AMES and hERG in vitro studies, which provide strong support for the safety and tolerability of NYR-BI03. These results mark a significant milestone in the development of NYR-BI03 as a potential neuroprotection treatment for traumatic brain injury and stroke. We are encouraged by the progress and remain committed to advancing the program towards the commencement of the Phase I clinical trial later this year.

Summary of Nyrada Inc (ASX: $NYR) Brain Injury program update

Nyrada Inc (ASX: $NYR) has made significant progress in its Brain Injury program with the completion of key safety studies for its lead drug candidate NYR-BI03. The positive outcomes of the AMES and hERG in vitro studies under GLP conditions demonstrate the safety and tolerability of NYR-BI03, supporting its potential as a neuroprotection treatment for traumatic brain injury and stroke. With the remaining GLP studies ongoing and the expectation of commencing the first in-human Phase I clinical trial in late 2QFY2025, Nyrada is focused on advancing the development of NYR-BI03. The Company remains committed to addressing the considerable unmet clinical need in the treatment of brain injury, reflecting its dedication to improving patient outcomes in this therapeutic area.